Financial Snapshot

Revenue
$0.00
TTM
Gross Margin
Net Earnings
-$119.9M
TTM
Current Assets
Q3 2024
Current Liabilities
Q3 2024
Current Ratio
1315.08%
Q3 2024
Total Assets
Q3 2024
Total Liabilities
Q3 2024
Book Value
$274.0M
Q3 2024
Cash
Q3 2024
P/E
-5.769
Nov 29, 2024 EST
Free Cash Flow
-$109.9M
TTM

Revenues

Revenues

Loading...

Revenue YoY Change

Loading...

Revenues

Concept 2023 2022 2021 2020 2019 2018
Revenue $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change

Expenses

Cost Of Revenues

Loading...

Gross Profit

Loading...

Gross Profit Margin

Loading...

Gross Profit

Concept 2023 2022 2021 2020 2019 2018
Revenue $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Cost Of Revenue
Gross Profit
Gross Profit Margin

Selling, General & Admin Expense

Loading...

Research & Development

Loading...

Depreciation, Depletion & Amortization

Loading...

SGA Expense to Gross Profit Ratio

Loading...

R&D To Gross Profit Ratio

Loading...

DDA To Gross Profit Ratio

Loading...

Operating Expenses Total

Loading...

Operating Profits/Loss

Loading...

Operational Expenses

Concept 2023 2022 2021 2020 2019 2018
Selling, General & Admin $25.61M $25.09M $22.01M $13.42M $5.730M $3.350M
YoY Change 2.08% 13.96% 64.03% 134.21% 71.04%
% of Gross Profit
Research & Development $85.17M $61.68M $56.86M $35.92M $22.84M $19.03M
YoY Change 38.09% 8.48% 58.29% 57.24% 20.07%
% of Gross Profit
Depreciation & Amortization $1.032M $1.000M $900.0K $1.000M $1.000M $900.0K
YoY Change 3.2% 11.11% -10.0% 0.0% 11.11%
% of Gross Profit
Operating Expenses $110.8M $91.77M $78.87M $74.19M $28.57M $22.37M
YoY Change 20.72% 16.35% 6.32% 159.67% 27.71%
Operating Profit -$110.8M -$91.77M -$78.87M -$74.19M -$28.57M -$22.37M
YoY Change 20.72% 16.35% 6.32% 159.67% 27.71%

Interest Expenses

Loading...

Interest Expenses To Operating Income %

Loading...

Other Expense/Income

Loading...

Interest & Other Expense/Income

Concept 2023 2022 2021 2020 2019 2018
Interest Expense $10.08M $2.645M $141.0K $306.0K $1.397M $775.0K
YoY Change 281.21% 1775.89% -53.92% -78.1% 80.26%
% of Operating Profit
Other Income/Expense, Net $10.08M $2.645M $156.0K $483.0K $1.686M $1.008M
YoY Change 281.21% 1595.51% -67.7% -71.35% 67.26%

Income/Loss

Pretax Income

Loading...

Income Tax

Loading...

Net Profits/Loss

Loading...

Pretax Income YoY Change

Loading...

Income Tax Rate

Loading...

Net Profits/Loss YoY Change

Loading...

Basic EPS

Loading...

Net Income To Revenue Ratio

Loading...

Pretax & Net Income

Concept 2023 2022 2021 2020 2019 2018
Pretax Income -$100.7M -$89.12M -$78.72M -$73.70M -$26.88M -$21.36M
YoY Change 12.99% 13.22% 6.8% 174.18% 25.84%
Income Tax $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$100.7M -$89.12M -$78.72M -$73.70M -$26.88M -$21.36M
YoY Change 12.99% 13.22% 6.8% 174.16% 25.84%
Net Earnings / Revenue
Basic Earnings Per Share -$1.96 -$2.25 -$2.07
Diluted Earnings Per Share -$1.96 -$2.25 -$2.074M -$3.359M -$976.0K -$775.6K

Assets & Liabilities

Cash & Short-Term Investments

Loading...

Cash & Equivalents

Loading...

Cash To Operating Expenses Ratio

Loading...

Inventory

Loading...

Receivables

Loading...

Total Short-Term Assets

Loading...

Property, Plant And Equipment

Loading...

Long-Term Investments

Loading...

Total Long-Term Assets

Loading...

Total Assets

Loading...

Net Income To Total Assets Percentage

Loading...

Accounts Payable

Loading...

Short-Term Debt

Loading...

Long Term Debt Due

Loading...

Total Short-Term Liabilities

Loading...

Long-Term Debt

Loading...

Other Long-Term Liabilities

Loading...

Total Long-Term Liabilities

Loading...

Total Liabilities

Loading...

Short-Term To Long-Term Debt Ratio

Loading...

Short-Term Assets To Debt Ratio

Loading...

Long-Term Debt To Net Income Ratio

Loading...

Assets & Liabilities

Concept 2023 2022 2021 2020 2019 2018
Cash & Short-Term Investments $208.2M $206.3M $237.0M $293.6M $89.20M $42.60M
YoY Change 0.93% -12.96% -19.29% 229.15% 109.39%
Cash & Equivalents $23.38M $66.84M $226.0M $78.40M $89.20M $42.60M
Short-Term Investments $184.8M $139.4M $10.97M $215.2M
Other Short-Term Assets $4.410M $4.185M $3.543M $3.100M $800.0K $1.100M
YoY Change 5.38% 18.12% 14.29% 287.5% -27.27%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $212.6M $210.5M $240.5M $296.7M $90.00M $43.70M
YoY Change 1.02% -12.5% -18.93% 229.67% 105.95%
Property, Plant & Equipment $2.862M $3.253M $2.413M $2.000M $2.200M $2.500M
YoY Change -12.02% 34.81% 20.65% -9.09% -12.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $26.85M $21.95M $43.39M
YoY Change 22.33% -49.41%
Other Assets $9.696M $11.52M $12.32M $300.0K $1.900M $500.0K
YoY Change -15.81% -6.53% 4007.0% -84.21% 280.0%
Total Long-Term Assets $39.41M $36.72M $58.12M $2.300M $4.100M $3.000M
YoY Change 7.32% -36.82% 2426.96% -43.9% 36.67%
Total Assets $252.0M $247.2M $298.6M $299.0M $94.10M $46.70M
YoY Change
Accounts Payable $944.0K $1.320M $1.886M $800.0K $200.0K $400.0K
YoY Change -28.48% -30.01% 135.75% 300.0% -50.0%
Accrued Expenses $19.51M $14.07M $13.27M $7.700M $4.700M $1.600M
YoY Change 38.71% 6.05% 72.27% 63.83% 193.75%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $20.46M $15.39M $15.15M $9.000M $5.400M $2.600M
YoY Change 32.95% 1.56% 68.34% 66.67% 107.69%
Long-Term Debt $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $7.461M $9.439M $10.52M $200.0K $800.0K $1.300M
YoY Change -20.96% -10.23% 5157.5% -75.0% -38.46%
Total Long-Term Liabilities $7.461M $9.439M $10.52M $200.0K $800.0K $1.300M
YoY Change -20.96% -10.23% 5157.5% -75.0% -38.46%
Total Liabilities $27.92M $24.83M $25.67M $9.200M $6.100M $3.900M
YoY Change 12.45% -3.27% 178.98% 50.82% 56.41%

Ownership

Basic Shares Outstanding

Loading...

Diluted Shares Outstanding

Loading...

Preferred Stock

Loading...

Treasury Stock Shares

Loading...

Stock Issuance & Repurchase

Loading...

Ownership Data

Concept 2023 2022 2021 2020 2019 2018
Basic Shares Outstanding 51.45M 39.66M 37.95M
Diluted Shares Outstanding 51.45M 39.66M 37.95M
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Loading...

Book Value

Loading...

Free Cash Flow

Loading...

Free Cash Flow YoY

Loading...

Free Cash Flow Margin

Loading...

Dividends

Dividends

Loading...

Stock Price

Loading...
Market Cap: $691.56 Million

About Oric Pharmaceuticals, Inc.

Oric Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development of cancer treatments that address mechanisms of therapeutic resistance. The company is headquartered in South San Francisco, California and currently employs 112 full-time employees. The company went IPO on 2020-04-24. The company is developing a pipeline of clinical and discovery stage therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology and key tumor dependencies. Its clinical-stage product candidates include ORIC-114, a brain penetrant inhibitor designed to selectively target EGFR and HER2 with high potency against exon 20 insertion mutations, being developed across multiple genetically defined cancers, ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens.

Industry: Pharmaceutical Preparations Peers: Astria Therapeutics, Inc. AVITA Medical, Inc. Celcuity Inc. DermTech, Inc. Icosavax, Inc. Olema Pharmaceuticals, Inc. PepGen Inc. Ovid Therapeutics Inc. Tenaya Therapeutics, Inc.